PT - JOURNAL ARTICLE AU - Denissen, Stijn AU - Van Laethem, Delphine AU - Baijot, Johan AU - Costers, Lars AU - Descamps, Annabel AU - Van Remoortel, Ann AU - Van Merhaegen-Wieleman, Annick AU - D’hooghe, Marie B AU - D’Haeseleer, Miguel AU - Smeets, Dirk AU - Sima, Diana Maria AU - Van Schependom, Jeroen AU - Nagels, Guy TI - icognition: a smartphone-based cognitive screening battery AID - 10.1101/2023.07.19.23292824 DP - 2023 Jan 01 TA - medRxiv PG - 2023.07.19.23292824 4099 - http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292824.short 4100 - http://medrxiv.org/content/early/2023/07/23/2023.07.19.23292824.full AB - Background Telemedicine is feasible and well-accepted by people with multiple sclerosis (MS).Objective The aim of this study is to validate a smartphone-based cognitive screening battery, icognition, to faster signal cognitive deterioration.Methods icognition consists of three tests (Symbol Test, Dot Test and visual Backwards Digit Span (vBDS)) that are equivalents of validated paper-pencil tests. These are the Symbol Digit Modalities Test (SDMT), the 10/36 Spatial Recall Test (SPART) and the auditory Backwards Digit Span (aBDS), respectively. To establish the validity of icognition, 101 people with MS and 82 healthy subjects completed all tests. 21 healthy subjects repeated testing 2 to 3 weeks later.Results All tests in icognition correlate well with their paper-pencil equivalent (Symbol Test: r=.63, p<.001; Dot Test: r=.31, p=0.002; vBDS: r=.71, p<.001), negatively correlate with the Expanded Disability Status Scale (EDSS: Symbol Test: rho=-.27, p=.01; Dot Test: rho=-.29, p=.006; vBDS: rho=- .23, p=.027) and show high test-retest reliability (Symbol Test: r=.81, p<.001; Dot Test: r=.75, p<.001; vBDS: r=.84, p<.001). Test performance was not significantly different between people with MS and healthy subjects for all cognitive tests, both in icognition and their paper-pencil equivalents.Conclusion icognition is a valid and reliable tool to remotely screen for cognitive functioning in persons with MS.Competing Interest StatementStijn Denissen pursues an industrial PhD trajectory in collaboration with icometrix. Lars Costers, Annabel Descamps, Dirk Smeets and Diana M Sima are employees of icometrix. Guy Nagels is on a 10% secondment as medical director neurology from UZ Brussel to icometrix. Guy Nagels and Dirk Smeets are shareholders of icometrix.Funding StatementStijn Denissen is funded by a Baekeland grant from Flanders Innovation and Entrepreneurship (VLAIO, HCB.2019.2579). Both Delphine van Laethem (1SD5322N) and Guy Nagels (1805620N) are supported by a personal grant appointed by the Fonds Wetenschappelijk Onderzoek (FWO) Flanders. This study is partly funded by the CLAIMS project, supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112153. The JU is supported by the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, AB Science SA and icometrix NV.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the "Commissie Medische Ethiek" of the UZ Brussel (B.U.N. 143201940335) and the National MS Center of Melsbroek. All participants signed informed consent prior to inclusion.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data upon which this study relies will be made publicly available in the GitHub repository of our lab: https://github.com/AIMS-VUB/smartphone_tests https://github.com/AIMS-VUB/smartphone_tests